BIOFILCHEM.NS
Biofil Chemicals and Pharmaceuticals Limited [BIOFILCHEM.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BIOFILCHEM.NS Stock Summary
Top 10 Correlated ETFs
BIOFILCHEM.NS
Top 10 Correlated Stocks
BIOFILCHEM.NS
In the News
BIOFILCHEM.NS Financial details
Company Rating
Buy
Market Cap
1.1B
Income
6.69M
Revenue
384.48M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
47
Optionable
No
Shortable
Yes
Earnings
12 Feb 2024
P/E
132.3
Forward P/E
-
PEG
-330.75
P/S
2.71
P/B
5.06
P/C
-
P/FCF
-
Quick Ratio
1.14
Current Ratio
1.38
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.41
EPS next Y
-
EPS next Q
-
EPS this Y
-20.93%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
2.53%
Revenue last 5Y
5.36%
Revenue Q/Q
-71.03%
EPS Q/Q
-24.11%
-
-
-
-
SMA20
6.35%
SMA50
-
SMA100
36.73%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
8%
ROC
0.05%
Gross Margin
7%
Oper. Margin
3%
Profit Margin
2%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
41.3-79.0
52W High
-13.1%
52W Low
+67.44%
RSI
59
Rel Volume
0.37
Avg Volume
179.95K
Volume
66.27K
Perf Week
1.33%
Perf Month
6.85%
Perf Quarter
44.68%
Perf Half Y
35.94%
-
-
-
-
Beta
2.391
-
-
Volatility
1.08%, 4.07%
Prev Close
-0.07%
Price
68.65
Change
6.85%
BIOFILCHEM.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 14.21 | 18.24 | 21.97 | 13.75 | 18.46 | |
| Net income per share | 0.3 | 0.74 | 0.76 | 0.43 | 0.34 | |
| Operating cash flow per share | 0.77 | 0.64 | 0.68 | -0.14 | -0.07 | |
| Free cash flow per share | -0.1 | 0.51 | 0.33 | -0.18 | -0.08 | |
| Cash per share | 0.08 | 0.16 | 0.54 | 0.13 | 0.02 | |
| Book value per share | 8.39 | 9.15 | 9.91 | 10.35 | 10.63 | |
| Tangible book value per share | 8.39 | 9.15 | 9.91 | 10.35 | 10.63 | |
| Share holders equity per share | 8.39 | 9.15 | 9.91 | 10.35 | 10.63 | |
| Interest debt per share | 1.1 | 0.81 | 0.3 | 0.31 | 0.35 | |
| Market cap | 113.92M | 122.05M | 1.07B | 938.18M | 673.74M | |
| Enterprise value | 128.93M | 131.41M | 1.07B | 941.38M | 678.7M | |
| P/E ratio | 23.62 | 10.11 | 86.33 | 134.33 | 120.22 | |
| Price to sales ratio | 0.49 | 0.41 | 3 | 4.19 | 2.24 | |
| POCF ratio | 9.07 | 11.7 | 96.47 | -426.64 | -602.63 | |
| PFCF ratio | -72.65 | 14.59 | 196.92 | -323.74 | -550.44 | |
| P/B Ratio | 0.83 | 0.82 | 6.64 | 5.57 | 3.89 | |
| PTB ratio | 0.83 | 0.82 | 6.64 | 5.57 | 3.89 | |
| EV to sales | 0.56 | 0.44 | 3 | 4.21 | 2.26 | |
| Enterprise value over EBITDA | 11.47 | 6.51 | 44.71 | 63.55 | 53.67 | |
| EV to operating cash flow | 10.27 | 12.6 | 96.46 | -428.1 | -607.06 | |
| EV to free cash flow | -82.22 | 15.71 | 196.9 | -324.84 | -554.49 | |
| Earnings yield | 0.04 | 0.1 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | -0.01 | 0.07 | 0.01 | 0 | 0 | |
| Debt to equity | 0.12 | 0.08 | 0.03 | 0.03 | 0.03 | |
| Debt to assets | 0.07 | 0.03 | 0.01 | 0.02 | 0.02 | |
| Net debt to EBITDA | 1.34 | 0.46 | 0 | 0.22 | 0.39 | |
| Current ratio | 1.32 | 1.17 | 1.4 | 6.23 | 1.63 | |
| Interest coverage | 4.6 | 12.89 | 30.57 | 26.52 | 19.62 | |
| Income quality | 2.1 | 0.71 | 0.58 | -0.22 | -0.14 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0.01 | 0.01 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -1.12 | -0.2 | -0.51 | 0.32 | 0.09 | |
| Capex to revenue | -0.06 | -0.01 | -0.02 | 0 | 0 | |
| Capex to depreciation | -3.87 | -0.48 | -1.36 | -0.16 | -0.02 | |
| Stock based compensation to revenue | 0 | 0 | 0.01 | 0 | 0 | |
| Graham number | 7.48 | 12.35 | 13.04 | 10 | 9.08 | |
| ROIC | 0.04 | 0.08 | 0.08 | 0.04 | 0.03 | |
| Return on tangible assets | 0.02 | 0.03 | 0.04 | 0.04 | 0.02 | |
| Graham Net | -0.42 | -2.42 | -0.04 | 2.87 | 1.18 | |
| Working capital | 33.56M | 47.91M | 67.09M | 78.18M | 86.8M | |
| Tangible asset value | 136.5M | 148.83M | 161.29M | 168.38M | 173.02M | |
| Net current asset value | 33.56M | 47.91M | 63.52M | 74.19M | 83.01M | |
| Invested capital | 0.12 | 0.08 | 0.03 | 0.03 | 0.03 | |
| Average receivables | 60.96M | 210.59M | 243.01M | 131.52M | 140.65M | |
| Average payables | 88.63M | 172.5M | 208.85M | 82.24M | 66.23M | |
| Average inventory | 11.08M | 14.42M | 30.18M | 28.19M | 12.53M | |
| Days sales outstanding | 192.42 | 367.88 | 190.68 | 124.38 | 249.16 | |
| Days payables outstanding | 156.71 | 373.78 | 178.43 | 11.18 | 165.51 | |
| Days of inventory on hand | 21.74 | 24.4 | 48.9 | 24.26 | 15.88 | |
| Receivables turnover | 1.9 | 0.99 | 1.91 | 2.93 | 1.46 | |
| Payables turnover | 2.33 | 0.98 | 2.05 | 32.64 | 2.21 | |
| Inventory turnover | 16.79 | 14.96 | 7.46 | 15.05 | 22.99 | |
| ROE | 0.04 | 0.08 | 0.08 | 0.04 | 0.03 | |
| Capex per share | -0.87 | -0.13 | -0.35 | -0.04 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.92 | 8.37 | 1.5 | 10.67 | 3.09 | |
| Net income per share | 0.06 | 0.13 | 0.15 | 0.08 | 0.06 | |
| Operating cash flow per share | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | |
| Free cash flow per share | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | |
| Cash per share | 0.1 | 0.02 | 0.02 | 0.04 | 0 | |
| Book value per share | 10.5 | 10.63 | 10.63 | 10.86 | 0 | |
| Tangible book value per share | 0 | 10.63 | 0 | 10.86 | 0 | |
| Share holders equity per share | 10.5 | 10.63 | 10.63 | 10.86 | 0 | |
| Interest debt per share | 0.01 | 0.33 | 0.01 | 0.35 | 0 | |
| Market cap | 898.31M | 673.74M | 722.56M | 790.09M | 878.79M | |
| Enterprise value | 899.92M | 678.7M | 722.93M | 795.39M | 878.79M | |
| P/E ratio | 224.35 | 80.74 | 73.97 | 160.72 | 235.47 | |
| Price to sales ratio | 60.11 | 4.95 | 29.69 | 4.55 | 17.47 | |
| POCF ratio | 420.17 | 310.48 | 336.7 | 368.17 | 409.5 | |
| PFCF ratio | 420.17 | 310.48 | 336.7 | 368.17 | 409.5 | |
| P/B Ratio | 5.26 | 3.89 | 4.18 | 4.47 | 0 | |
| PTB ratio | 5.26 | 3.89 | 4.18 | 4.47 | 0 | |
| EV to sales | 60.22 | 4.98 | 29.71 | 4.58 | 17.47 | |
| Enterprise value over EBITDA | 358.25 | 153.76 | 163.41 | 294.7 | 398.18 | |
| EV to operating cash flow | 420.92 | 312.76 | 336.87 | 370.64 | 409.5 | |
| EV to free cash flow | 420.92 | 312.76 | 336.87 | 370.64 | 409.5 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0.03 | 0 | 0.03 | 0 | |
| Debt to assets | 0 | 0.02 | 0 | 0.01 | 0 | |
| Net debt to EBITDA | 0.64 | 1.12 | 0.09 | 1.96 | 0 | |
| Current ratio | 0 | 1.63 | 0 | 1.38 | 0 | |
| Interest coverage | 13.61 | 33.29 | 30.74 | 16.76 | 1.13K | |
| Income quality | 2.14 | 1.04 | 0.88 | 1.75 | 2.3 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.02 | 0.01 | 0.05 | 0.01 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.81 | 5.54 | 5.99 | 4.3 | 0 | |
| ROIC | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Return on tangible assets | 0 | 0.01 | 0 | 0 | 0 | |
| Graham Net | 0.1 | 1.18 | 0.02 | -0.86 | 0 | |
| Working capital | 1.61M | 86.8M | 377K | 92.63M | 0 | |
| Tangible asset value | 0 | 173.02M | 0 | 176.7M | 0 | |
| Net current asset value | 1.61M | 83.01M | 377K | 88.84M | 0 | |
| Invested capital | 0 | 0.03 | 0 | 0.03 | 0 | |
| Average receivables | 111.56M | 102.51M | 102.51M | 136.99M | 136.99M | |
| Average payables | 74.68M | 63.25M | 63.25M | 116.44M | 116.44M | |
| Average inventory | 4.51M | 6.07M | 6.07M | 25.37M | 25.37M | |
| Days sales outstanding | 0 | 135.52 | 0 | 141.98 | 0 | |
| Days payables outstanding | 0 | 88.1 | 0 | 124.31 | 0 | |
| Days of inventory on hand | 0 | 8.45 | 0 | 27.08 | 0 | |
| Receivables turnover | 0 | 0.66 | 0 | 0.63 | 0 | |
| Payables turnover | 0 | 1.02 | 0 | 0.72 | 0 | |
| Inventory turnover | 0 | 10.65 | 0 | 3.32 | 0 | |
| ROE | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
BIOFILCHEM.NS Frequently Asked Questions
What is Biofil Chemicals and Pharmaceuticals Limited stock symbol ?
Biofil Chemicals and Pharmaceuticals Limited is a IN stock and trading under the symbol BIOFILCHEM.NS
What is Biofil Chemicals and Pharmaceuticals Limited stock quote today ?
Biofil Chemicals and Pharmaceuticals Limited stock price is $68.65 today.
Is Biofil Chemicals and Pharmaceuticals Limited stock public?
Yes, Biofil Chemicals and Pharmaceuticals Limited is a publicly traded company.
Something similar
Company Profile
- Volume Average 179.95K
- Market Capitalization 1.1B
- Employee 47
- CEO Mr. Ramesh S. Shah
- Headquarters Indore,IN
- IPO Date 2017-07-27
-
Website
https://www.biofilgroup.net 
Biofil Chemicals and Pharmaceuticals Limited engages in the pharmaceutical and chemical businesses primarily in India. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and plastic dippers and caps. It also provides job work service for manufacturing of pharmaceuticals. The company was incorporated in 1985 and is based in Indore, India.
